Pharmaceutical manufacturing

What life sciences companies need to know

The coronavirus pandemic has caused major disruptions to commercial life science companies conducting clinical trials. To effectively plan the continuation of trials during this period, companies must first consider the Food and Drug Administration (FDA) and European Medicines Agency (EMA) COVID-19 guidance documents and consider what resources are available to effectively manage patient visits during this pandemic in order to conform to the relevant regulatory requirements.

Listen to Baker Tilly’s on-demand webinar for an informative discussion that will address:

  • How study teams can maintain clinical trial continuity through various remote/virtual or centralized solutions
  • Supply chain disruption and strategies organizations can adopt to ensure trial participants have uninterrupted access to study drug  
  • The future state of clinical affairs and the key considerations companies should make now to adapt to the new normal

Coronavirus Resource Center

For more information on this topic, or to learn how Baker Tilly's Value Architects™ can help, contact our team.

Reflection of building on a city skyscraper
Next up

A roundtable discussion on COVID-19 … and its impact on the metal forming and fabricating industry